Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market was valued at USD 5.5 billion in the year 2020. The key factors driving growth in the global Gastroesophageal Reflux Disease Therapeutics market is increased public awareness of the disease and its symptoms. The growing incidence of heartburn is likely to create new economic prospects for acid-reducing medications and proton pump inhibitors, resulting in the rapid growth of GERD therapeutics market. Other potential includes an increase in risk of GERD disease in emerging nations and technological advancements that allow for speedier diagnosis of the condition.
Protein pump inhibitors (PPIs) are the front line therapy for the treatment of GERD. The market of GERD is very large in the US and in European countries and mostly catered by PPIs. Although PPIs control the major share of the market but with PPIs providing limited relief and the treatment generally relapsing within 6-months, the market for acid blockers like Vonoprazan looks very lucrative with physicians also supports its efficacy in GERD management. Also, the US GERD market is highly price sensitive because of the availability of generics in the market and hence any drug, even with higher efficiency, will have to price rationally to gain share of the market.
The increasing prevalence of gastroesophageal reflux disease is correlated with the increasing prevalence of obesity in many countries and presence of other poor diet and lifestyle factors. Several environmental factors and the prominent lifestyle evolution to sedentary habits such as a high dietary fat intake, shorter dinner-to-bed time, and frequent smoking and alcohol consumption have been proven as the high risk factors associated with the prevalence of gastroesophageal reflux diseases.
North America region dominates the Gastroesophageal Reflux Disease Therapeutics Market. High incidence of obesity-driven GERD and innovation in drugs in GERD treatments are factors that have helped cement the potential of the North America GERD therapeutics market. Moreover, high per capita expenditure on healthcare coupled with extended life expectancy of consumers in the region has been creating a sustainable demand for the superior treatment for the GERD in North America.
Scope of the Report
- The report presents the analysis of Gastroesophageal Reflux Disease Therapeutics Market for the historical period of 2016-2020 and the forecast period of 2021-2026.
- The report analyses the Gastroesophageal Reflux Disease Therapeutics Market by Drug Type (Antacids, H2 Receptor Blockers and Proton Pump Inhibitors) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies).
- The major regional markets (North America, Europe, Asia Pacific) have been analysed, along with country coverage of North America, Europe and Asia Pacific) and By Country (United States, Canada, Germany, France, United Kingdom, Spain, Italy, China, Japan and India.
- The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.
- The competitive landscape of the market, along with the company profiles of leading players (Phathom Pharmaceuticals, Eisai, Takeda Pharmaceutical Company, Daewoong Pharmaceutical, Ironwood Pharmaceuticals, Johnson & Johnson, EndoGastric Solutions, CHEPLAPHARM Arzneimittel, Merck & Co. and Olympus Corporation.) are also presented in detail.
Key Target Audience
- Gastroesophageal Reflux Disease Drug Manufacturers
- Pharmaceutical Industry
- Biotechnology Companies
- Pharmacies, and Retailers
- Government and Research Organisations
- Consulting and Advisory Firms
- Investment Banks and Equity Firms
Table of Contents
1. Research Methodology and Executive Summary1.1 Research Methodology
1.2 Executive Summary
1. Report scope & Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Global Gastroesophageal Reflux Disease Therapeutics Market Product Overview
4. Global Gastroesophageal Reflux Disease Therapeutics Market: An Analysis
4.1 Market Size, By Value, Year 2016-2026
4.2 COVID-19 Impact on Gastroesophageal Reflux Disease Therapeutics Market
5. Global Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type (By Value)
5.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Drug Type
5.2 Antacids– Market Size and Forecast (2016-2026)
5.3 H2 Receptor Blockers– Market Size and Forecast (2016-2026)
5.4 Proton Pump Inhibitors– Market Size and Forecast (2016-2026)
6. Global Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Distribution Channel (By Value)
6.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Distribution Channel
6.2 Hospital Pharmacies– Market Size and Forecast (2016-2026)
6.3 Retail Pharmacies– Market Size and Forecast (2016-2026)
6.4 Online Pharmacies– Market Size and Forecast (2016-2026)
7. Global Gastroesophageal Reflux Disease Therapeutics Market: Regional Analysis
7.1 Competitive Scenario of Global Gastroesophageal Reflux Disease Therapeutics Market: By Region
8. North America Gastroesophageal Reflux Disease Therapeutics Market: An Analysis (2016-2026)
8.1 North America Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
8.2 North America Gastroesophageal Reflux Disease Therapeutics Market – Prominent Companies
8.3 Market Segmentation By Drug Type (Antacids, H2 Receptor Blockers and Proton Pump Inhibitors)
8.4 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
8.5 North America Gastroesophageal Reflux Disease Therapeutics Market: Country Analysis
8.6 Market Opportunity Chart of North America Gastroesophageal Reflux Disease Therapeutics Market - By Country, By Value (Year-2026)
8.7 Competitive Scenario of North America- By Country
8.8 United States Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
8.9 Prominent Companies in Gastroesophageal Reflux Disease Therapeutics Market
8.10 United States Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
8.11 Canada Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
8.12 Canada Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
9. Europe Gastroesophageal Reflux Disease Therapeutics Market: An Analysis (2016-2026)
9.1 Europe Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
9.2 Europe Gastroesophageal Reflux Disease Therapeutics Market – Prominent Companies
9.3 Market Segmentation By Drug Type (Antacids, H2 Receptor Blockers and Proton Pump Inhibitors)
9.4 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
9.5 Europe Gastroesophageal Reflux Disease Therapeutics Market: Country Analysis
9.6 Market Opportunity Chart of Europe Gastroesophageal Reflux Disease Therapeutics Market - By Country, By Value (Year-2026)
9.7 Competitive Scenario of Europe- By Country
9.8 Germany Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
9.9 Prominent Companies in Gastroesophageal Reflux Disease Therapeutics Market
9.10 Germany Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
9.11 France Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
9.12 France Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
9.13 United Kingdom Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
9.14 Prominent Companies in Gastroesophageal Reflux Disease Therapeutics Market
9.15 United Kingdom Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
9.16 Italy Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
9.17 Italy Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
9.18 Spain Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
9.19 Spain Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
10. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market: An Analysis (2016-2026)
10.1 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
10.2 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market – Prominent Companies
10.3 Market Segmentation By Drug Type (Antacids, H2 Receptor Blockers and Proton Pump Inhibitors)
10.4 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
10.5 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market: Country Analysis
10.6 Market Opportunity Chart of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market - By Country, By Value (Year-2026)
10.7 Competitive Scenario of Asia Pacific- By Country
10.8 China Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
10.9 China Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
10.10 Japan Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
10.11 Prominent Companies in Gastroesophageal Reflux Disease Therapeutics Market
10.12 Japan Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
10.13 India Gastroesophageal Reflux Disease Therapeutics Market: Size and Forecast (2016-2026), By Value
10.14 India Gastroesophageal Reflux Disease Therapeutics Market Segmentation By Drug Type and Distribution Channel.
11. Global Gastroesophageal Reflux Disease Therapeutics Market Dynamics
11.1 Global Gastroesophageal Reflux Disease Therapeutics Market Drivers
11.2 Global Gastroesophageal Reflux Disease Therapeutics Market Restraints
11.3 Global Gastroesophageal Reflux Disease Therapeutics Market Trends
12. Market Attractiveness
12.1 Market Attractiveness Chart of Global Gastroesophageal Reflux Disease Therapeutics Market – By Drug Type, By Value (Year-2026)
12.2 Market Attractiveness Chart of Global Gastroesophageal Reflux Disease Therapeutics Market – By Distribution Channel, By Value (Year-2026)
12.3 Market Attractiveness Chart of Global Gastroesophageal Reflux Disease Therapeutics Market – By Region, By Value (Year-2026)
13. Competitive Landscape
13.1 Market Share Analysis
13.2 Gastroesophageal Reflux Disease Therapeutics Pipeline
14. Company Profiles (Business Description, Financial Analysis, Business Strategy)
14.1 Phathom Pharmaceuticals
14.2 Eisai
14.3 Takeda Pharmaceutical Company
14.4 Daewoong Pharmaceutical
14.5 Ironwood Pharmaceuticals
14.6 Johnson & Johnson
14.7 EndoGastric Solutions
14.8 CHEPLAPHARM Arzneimittel
14.9 Merck & Co.
14.10 Olympus CorporationList of Figures
- Global Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)
- Projected global population (In Billions)
- Population ages 65 and above, By Select Region, 2016-2020 (% of total)
- Projected global population aged 60 years & above (In Billions)
- Prevalence of Gastroesophageal Reflux Disease , By Region, 2017 (In %)
- Prevalence of GERD and Estimated Population in United States and EU 5
- Global Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type Market Share, 2020 & 2026
- Global Gastroesophageal Reflux Disease Therapeutics Market- By Antacids, By Value (USD Million), 2016-2026
- Global Gastroesophageal Reflux Disease Therapeutics Market- By H2 Receptor Blockers, By Value (USD Million), 2016-2026
- Global Gastroesophageal Reflux Disease Therapeutics Market- By Proton Pump Inhibitors, By Value (USD Million), 2016-2026
- Global Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel Market Share, 2020 & 2026
- Global Gastroesophageal Reflux Disease Therapeutics Market- By Hospital Pharmacies, By Value (USD Million), 2016-2026
- Global Gastroesophageal Reflux Disease Therapeutics Market- By Retail Pharmacies, By Value (USD Million), 2016-2026
- Global Gastroesophageal Reflux Disease Therapeutics Market- By Online Pharmacies, By Value (USD Million), 2016-2026
- Global Gastroesophageal Reflux Disease Therapeutics Market- By Region Market Share, 2020 & 2026
- North America Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)
- North America Healthcare Cost Per Capita, 2018 (USD)
- North America Population above 65 year, 2015, 2030F, & 2050F (In Millions)
- North America Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026
- North America Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026
- Market Opportunity Chart of North America Gastroesophageal Reflux Disease Therapeutics Market- By Country, By Value (Year-2026)
- North America Gastroesophageal Reflux Disease Therapeutics Market- By Country Market Share, 2020 & 2026
- United States Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)
- United States Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
- United States healthcare expenditure as percentage of GDP
- United States Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026
- United States Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026
- Canada Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)
- Canada Gastroesophageal Reflux Disease Facts
- Canada Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026
- Canada Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026
- Europe Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)
- Population ages 65 and above (% of total population) - European Union
- Gross domestic expenditure on R&D (GERD) as a % of GDP in selected European countries
- Per Capita Health Expenditure, By Select Country, 2018 (USD)
- Breakdown of Total Health Expenditure in Europe, 2018 (%)
- Europe Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026
- Europe Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026
- Market Opportunity Chart of Europe Gastroesophageal Reflux Disease Therapeutics Market- By Country, By Value (Year-2026)
- Europe Gastroesophageal Reflux Disease Therapeutics Market, By Country, 2020, 2026
- Germany Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)
- Germany Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026
- Germany Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026
- France Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)
- France Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026
- France Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026
- United Kingdom Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)
- United Kingdom Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026
- United Kingdom Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026
- Italy Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)
- Share of individuals affected by gastroesophageal reflux disease in Italy in 2009 and 2018
- Share of individuals affected by gastroesophageal reflux disease in Italy as of 2018, by gender
- Italy Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026
- Italy Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026
- Spain Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)
- Spain Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026
- Spain Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026
- Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)
- Population ages 65 and above, APAC Region, By Select Countries, 2017 (% of total)
- Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total)
- Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026
- Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026
- Market Opportunity Chart of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market- By Country, By Value (Year-2026)
- Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, By Country, 2020, 2026
- China Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)
- Share of overweight population in China as of 2019, by gender
- Share of adult population who smoke in China from 2014 to 2018, by gender
- China Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026
- China Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026
- Japan Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)
- Vonoprazan Sales in Japan, in USD Million from 2015 - 2020
- Japan Healthcare Expenditure Outlook (%)
- Japan Median Age of population from 2010 to 2050 (in years)
- Top Pharma Companies In Japan, based on sales in 2019, USD Billions
- Domestic private health expenditure (% of current health expenditure) - Japan
- Japan Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026
- Japan Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026
- India Gastroesophageal Reflux Disease Therapeutics Market Size, By Value, 2016-2026 (USD Million)
- India Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type, By Value (USD Million), 2016-2026
- India Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel, By Value (USD Million), 2016-2026
- Market Attractiveness Chart of Global Gastroesophageal Reflux Disease Therapeutics Market- By Drug Type (Year-2026)
- Market Attractiveness Chart of Global Gastroesophageal Reflux Disease Therapeutics Market- By Distribution Channel (Year-2026)
- Market Attractiveness Chart of Global Gastroesophageal Reflux Disease Therapeutics Market- By Region (Year-2026)
- Global Gastroesophageal Reflux Disease Therapeutics company market share (%), 2020
- Eisai Annual Sales Revenue (USD Million), 2016-2020
- Eisai Annual Net Income/Loss (USD Million), 2016-2020
- Eisai sales Revenues, By Business Segment (%), FY2020
- Eisai sales Revenue, By Geographical Segment (%), FY2020
- Takeda Pharmaceutical Company Annual Sales Revenue (USD Million), 2016-2020
- Takeda Pharmaceutical Company Annual Net Income/Loss (USD Million), 2016-2020
- Takeda Pharmaceutical Company sales Revenues, By Business Segment (%), FY2020
- Takeda Pharmaceutical Company sales Revenue, By Geographical Segment (%), FY2020
- Daewoong Pharmaceutical Annual Sales Revenue (USD Million), 2016-2020
- Daewoong Pharmaceutical Annual Net Income/Loss (USD Million), 2016-2020
- Ironwood Pharmaceuticals Annual Sales Revenue (USD Million), 2016-2020
- Ironwood Pharmaceuticals Annual Net Income/Loss (USD Million), 2016-2020
- Ironwood Pharmaceuticals sales Revenues, By Geography Segment (%), FY2019
- Ironwood Pharmaceuticals sales Revenue, By Geographical Segment (%), FY2020
- Johnson & Johnson Annual Sales Revenue (USD Million), 2016-2020
- Johnson & Johnson Annual Net Income/Loss (USD Million), 2016-2020
- Johnson & Johnson sales Revenues, By Business Segment (%), FY2020
- Johnson & Johnson sales Revenue, By Geographical Segment (%), FY2020
- Merck & Co. Annual Sales Revenue (USD Million), 2016-2020
- Merck & Co. Annual Net Income/Loss (USD Million), 2016-2020
- Merck & Co. sales Revenues, By Business Segment (%), FY2020
- Merck & Co. sales Revenue, By Geographical Segment (%), FY2020
- Olympus Corporation Annual Sales Revenue (USD Million), 2017-2020
- Olympus Corporation Annual Net Income/Loss (USD Million), 2017-2020
List of Tables
- Health expenditures in Germany as share of GDP and in millions of Euro
- % OF ADULT POPULATION WITH GASTROINTESTINAL CONDITIONS IN FRANCE
- % OF ADULT POPULATION WITH MEDICATION USAGE FOR GASTROINTESTINAL CONDITIONS IN FRANCE
- Factor for Gastrointestinal Conditions in United Kingdom based on the age group
- % OF ADULT POPULATION WITH GASTROINTESTINAL CONDITIONS IN SPAIN
- Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10)
- Upcoming potential pipeline catalysts
- Takecab (Takeda) the first-line therapy for GERD
